Back to Authors

Prota, Costantina

0000-0003-0393-9876

Mayo Clinic

San Luca Hospital, Vallo della Lucania, Italy.

Citations 1

Prognostic value of stress echocardiography assessed by the ABCDE protocol
Zagatina, A , Cortigiani, Lauro , Wierzbowska‐Drabik, Karina , Kasprzak, Jarosław D. , Djordjevic‐Dikic, Ana , Boshchenko, A , Ryabova, T. R. , Gaibazzi, Nicola , Rigo, Fausto , Dodi, Claudio , Simova, Iana , Samardjieva, Martina, Barbieri, Andréa , Lorenzoni, Valentina , Prota, Costantina , Villari, Bruno, Antonini‐Canterin, Francesco, Carpeggiani, Clara , Pellikka, Patricia A. , Picano, Eugenio , Zagatina, Angela , Cortigiani, Lauro , Wierzbowska-Drabik, Karina , Kasprzak, Jaroslaw D , Ryabova, Tamara , Gaibazzi, Nicola , Barbieri, Andrea , Lorenzoni, Valentina , Prota, Costantina , Pepi, Mauro , Carpeggiani, Clara , Pellikka, Patricia A , Picano, Eugenio , Boshchenko, Alla , Ciampi, Quirino , Haberka, Maciej , Beleslin, Branko , Morrone, Doralisa

European Heart Journal | July 14, 2021 | Volume: 42 | Issue: 37 | Pages: 3869-3878

10.1093/eurheartj/ehab493 Get It

Abstract Aim The aim of this study was to assess the prognostic value of ABCDE-SE in a prospective, large scale, multicentre, international, effectiveness study. Stress echocardiography (SE) was recently upgraded to the ABCDE protocol: step A, regional wall motion abnormalities; step B, B lines; step C, left ventricular contractile reserve; step D, Doppler-based coronary flow velocity reserve in left anterior descending coronary artery; and step E, electrocardiogram-based heart rate reserve. Methods and results From July 2016 to November 2020, we enrolled 3574 all-comers (age 65 ± 11 years, 2070 males, 58%; ejection fraction 60 ± 10%) with known or suspected chronic coronary syndromes referred from 13 certified laboratories. All patients underwent clinically indicated ABCDE-SE. The employed stress modality was exercise (n = 952, with semi-supine bike, n = 887, or treadmill, n = 65 with adenosine for step D) or pharmacological stress (n = 2622, with vasodilator, n = 2151; or dobutamine, n = 471). SE response ranged from score 0 (all steps normal) to score 5 (all steps abnormal). All-cause death was the only endpoint. Rate of abnormal results was 16% for A, 30% for B, 36% for C, 28% for D, and 37% for E steps. During a median follow-up of 21 months (interquartile range: 13–36), 73 deaths occurred. Global X 2 was 49.5 considering clinical variables, 50.7 after step A only (P = NS (not significant)) and 80.6 after B–E steps (P < 0.001 vs. step A). Annual mortality rate ranged from 0.4% person-year for score 0 up to 2.7% person-year for score 5. Conclusion ABCDE-SE allows an effective prediction of survival in patients with chronic coronary syndromes.